Confidence intervals for discrete data in clinical research.

If it turns out that more proportion of responders is observed from the test drug group than the control group, then the test drug can be approved for general patient population. In the clinical development of new drugs, research pharmaceutical industry and biotech companies (known as sponsors) design and execute clinical trials in order to evaluate the efficacy and safety of the study drug. When comparing the drug efficacy of two groups (e.g., test treatment vs. control), development teams often study the differences in the proportion of responders between these two treatments. In other words, the Phase III clinical trial is designed to compare a test drug against another drug for the same indication, and this other drug has already been approved by regulatory agencies. [Extracted from the article]